Links, Matthew

Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis

Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H. (2017) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 839

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis

Lee, C. K., Man, J., Lord, S., Cooper, W., Links, M., Gebski, V., Herbst, R. S., Gralla, R. J., Mok, T., & Yang, J. C.-H. (2018) · JAMA Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 598

Impact of Specific Epidermal Growth Factor Receptor ( EGFR ) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR -Mutant Lung Cancer: A Meta-Analysis

Lee, C. K., Wu, Y.-L., Ding, P. N., Lord, S. J., Inoue, A., Zhou, C., Mitsudomi, T., Rosell, R., Pavlakis, N., Links, M., et al. (2015) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 327

Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer

Pourgholami, M. H., Szwajcer, M., Chin, M., Liauw, W., Seef, J., Galettis, P., Morris, D. L., & Links, M. (2010) · Cancer Chemotherapy and Pharmacology

Cancer therapeutics and mechanismsCancer Treatment and Pharmacology

Cited by 69